Please assess the completion status of the following clinical trial:

Trial Title: Patient Empowered Strategy to Reduce Asthma Morbidity in Highly Impacted Populations; PeRson EmPowered Asthma RElief

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA~* Black or Hispanic based on self-identification (Hispanic if identify as both)~* Male and female, ages 18-75 years~* Ability to provide informed consent~* Clinical history consistent with asthma for \> 1 year.~* Prescribed ICS as daily maintenance therapy~* Participant must also have an ACT score of 19 or less, or a history of one or more exacerbations in the past year that required patient report of systemic corticosteroid use.~EXCLUSION CRITERIA~* Life expectancy less than one year~* Known allergy to the ICS inhaler used in the study~* Having COPD or other chronic lung disease other than asthma; with the exception of the following:~  * Dx of COPD in a never smoker without any other lung disease or any other disease that might cause airway obstruction such as: Cystic Fibrosis, Connective Tissue Disease, premature birth, organ transplantation, bronchiectasis, sarcoid, and obliterative bronchiolitis~ * Dx of COPD in former smoker with normal PFTs done after the person quit smoking~ * Dx of COPD in current smoker with normal PFTs done in past 24 months~ * Dx of COPD IN CURRENT OR FORMER SMOKER with obstruction on PFTs: normal diffusing capacity in past 24 months and demonstrated reversibility of 12% or more at any time~* Regular systemic corticosteroid use daily or every other day for any reason-including asthma or other medical reasons~* Use of systemic corticosteroid, or visit to the doctor's office, emergency department (ED) or urgent care, or overnight hospitalization for an asthma exacerbation in the past month (can wait and re-check eligibility after one month)~* Use of biologics (injections or infusion medicines): with the exception of the following:~  * the patient has been on a stable dose of a biologic for at least 6 months and,~ * must have had an exacerbation at least 2 months after starting on a biologic to be considered eligible OR~ * must have a current ACT score \<=19 to be considered eligible.~* Bronchial thermoplasty less than 6 months ago (can re-check eligibility 6 months after procedure)~* Another family member living in the same household already enrolled in study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PARTICS (Type: ACTIVE_COMPARATOR): addition of PARTICS strategy - Patient Activated Reliever-Triggered Inhaled CorticoSteroid (PARTICS) using QVAR . Patient will use inhaled corticosteroid at time of rescue inhaler use
- Usual Care (Type: NO_INTERVENTION): Provider-enhanced usual care arm; no change in asthma management

Based on this trial design, predict the completion outcome and termination type (if applicable).